Avalanche Biotechnologies Announces Leadership Transition
– Avalanche Co-founder
"Avalanche is a leader in developing gene therapy products for eye diseases, and we are grateful to Tom, who co-founded the Company and has played an instrumental role in Avalanche's progress, including steering the scientific development of the Ocular BioFactory™ technology platform and building a diverse pipeline with the potential to transform the standard of care across a number of diseases in ophthalmology," said Dr.
Avalanche's Board of Directors has appointed independent directors
"After nine years since co-founding the Company and serving as CEO, I am proud of the progress we've made," said Dr. Chalberg. "I am ready to turn over the reins to a new leader, and look forward to supporting the Company in a new role going forward. I am deeply thankful for the opportunity to work alongside such an incredibly talented group of colleagues on behalf of the millions of patients suffering from blinding and sight-threatening diseases."
In addition, Avalanche announced that co-founder
Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need. Avalanche's proprietary Ocular BioFactory™ is a platform for discovering and developing novel medicines with the potential to offer life-changing therapeutic benefit. Avalanche's lead product candidate, AVA-101, is in mid-stage clinical development for patients with wet age-related macular degeneration. For more information, please visit www.avalanchebiotech.com.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avalanche's plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development and the potential benefits of its products under development, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our product development program, clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process, including the risk that positive results from a clinical study of AVA-101 may not necessarily be predictive of the results of future clinical studies, the uncertainties inherent in the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our product candidates. Avalanche undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the business of Avalanche, see our Annual Report on Form 10-K for the year ended
CONTACT: Investor Contact
Lauren Glaser(650) 656-9347 firstname.lastname@example.org Media Contact Nicole Foderaro(415) 946-1058 email@example.com